Reuters logo
BRIEF-Advanced Accelerator announces European approval of lutetium oxodotreotide for gastroenteropancreatic neuroendocrine tumors
September 29, 2017 / 1:40 PM / 3 months ago

BRIEF-Advanced Accelerator announces European approval of lutetium oxodotreotide for gastroenteropancreatic neuroendocrine tumors

Sept 29 (Reuters) - Advanced Accelerator Applications SA :

* Advanced Accelerator Applications announces European approval of lutetium (177lu) oxodotreotide (lutathera®) for gastroenteropancreatic neuroendocrine (gep-net) tumors

* Advanced Accelerator - ‍approval allows for marketing of lutathera in all 28 EU member states, Iceland, Norway & liechtenstein​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below